Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, San Francisco, California, USA.
Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Japan.
Clin Pharmacol Ther. 2018 Nov;104(5):803-817. doi: 10.1002/cpt.1098. Epub 2018 May 31.
Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.
基因组技术的进步带来了大量的信息，确定了膜转运体中的遗传多态性，特别是这些多态性如何影响药物处置和反应。本综述描述了国际转运体协会（ITC）对膜转运体中临床重要多态性的当前观点。ITC 建议，除了先前在 ABCG2（BCRP）和 SLCO1B1（OATP1B1）中推荐的多态性外，还应在药物开发过程中考虑新兴转运体 SLC22A1（OCT1）中的多态性。这些转运体的多态性共同决定了许多药物的个体间水平、毒性和反应的差异。
